騰景科技(688195.SH):正在進行AR納米壓印衍射波導片及光機模組的產品技術開發及驗證
格隆匯7月19日丨騰景科技(688195.SH)披露投資者關係活動記錄表顯示,精密光學是AR應用領域的關鍵支撐技術之一,公司開發的稜鏡組合、模壓玻璃非球面透鏡、幾何光波導組件等精密光學元組件,目前已應用於AR設備中。同時公司正在進行AR納米壓印衍射波導片及光機模組的產品技術開發及驗證,逐步實現從光學元件、組件到光機模組的垂直整合能力。
目前,AR技術及應用處於發展初期,產業潛力大、技術跨度大、應用空間廣,隨着技術與行業應用的融合逐步加速,AR設備滲透率也將進一步提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.